SCHEMBL4877952

SCHEMBL4877952

COc1ccc(C2=NOC3(CCC3)C2)cc1OCC(N)=O

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 7/20 0.48
PDE4A P27815 5/20 0.48
PDE4C Q08493 5/20 0.48
PDE4D Q08499 5/20 0.48
MIF P14174 2/20 0.41
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
SSTR5 P35346 1/20 0.39
SNCA P37840 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTT P42858 1/20 0.38
F2 P00734 1/20 0.37
F10 P00742 1/20 0.37
PRSS1 P07477 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4867637 0.98 PDE4B (0.48) PDE4BPDE4APDE4CPDE4DMIF
SCHEMBL4877799 0.97 PDE4B (0.47) PDE4BPDE4APDE4CPDE4DMIF
SCHEMBL4878691 0.91 PDE4B (0.48) PDE4BPDE4APDE4CPDE4DMIF
SCHEMBL4867717 0.89 PDE4B (0.48) PDE4BPDE4APDE4CPDE4DMIF
SCHEMBL4874449 0.89 PDE4B (0.48) PDE4BPDE4APDE4CPDE4DMIF
SCHEMBL5247867 0.88 PDE4B (0.47) PDE4BPDE4APDE4CPDE4DMIF
SCHEMBL3677124 0.88 PDE4B (0.41) PDE4BPDE4APDE4CPDE4DMIF
SCHEMBL4877912 0.86 PDE4B (0.48) PDE4BPDE4APDE4CPDE4DMIF
SCHEMBL4877520 0.86 PDE4B (0.46) PDE4BPDE4APDE4CPDE4DMIF
SCHEMBL4876277 0.85 PDE4B (0.47) PDE4BPDE4APDE4CPDE4DMIF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080009535-A1 Inhibitors of phosphodiesterase type-IV RANBAXY LABORATORIES LIMITED (IN) 2008-01-10 US claimed
EP-1840123-A1 Isoxazolines and their use as inhibitors of phosphodiesterase type-IV Ranbaxy Laboratories Limited (IN) 2007-10-03 EP claimed
US-20080009535-A1 Inhibitors of phosphodiesterase type-IV RANBAXY LABORATORIES LIMITED (IN) 2008-01-10 US disclosed
EP-1840123-A1 Isoxazolines and their use as inhibitors of phosphodiesterase type-IV Ranbaxy Laboratories Limited (IN) 2007-10-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009535-A1 Inhibitors of phosphodiesterase type-IV PDE4A, PDE3B, PDE4B PDE4B 3/4885PDE4A 1/4885PDE4C 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.